Clinical Trials
5 trialsNCT02496663 2026-05-13
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03054038 2022-04-14
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT02451930 2020-10-05
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
Eli Lilly and Company
Phase 1 Completed
NCT02411591 2020-07-09
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed